Free Trial
NASDAQ:VIGL

Vigil Neuroscience Q3 2024 Earnings Report

Vigil Neuroscience EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Vigil Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vigil Neuroscience Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Vigil Neuroscience's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vigil Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vigil Neuroscience and other key companies, straight to your email.

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL) is a clinical-stage biopharmaceutical company focused on developing novel therapies to address neuroinflammation in debilitating neurodegenerative diseases. The company’s research centers on the TAM family of receptor tyrosine kinases, which regulate microglial activation and clearance processes in the central nervous system. By modulating these pathways, Vigil aims to slow or halt the progression of conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

Leveraging a proprietary discovery platform, Vigil identifies and optimizes small-molecule modulators with high specificity for TAM receptors and favorable brain penetration. Its lead candidates have demonstrated neuroprotective and anti-inflammatory effects in preclinical models and have progressed into early clinical development. Vigil plans to broaden its pipeline to additional indications where chronic neuroinflammation plays a key role.

Founded in 2019 and headquartered in New York City, Vigil Neuroscience is led by a team of seasoned professionals in neuroscience, drug discovery and clinical development. The company collaborates with academic institutions and industry partners and is supported by venture investors with deep expertise in life sciences, all with the shared goal of delivering transformative therapies for patients living with neurodegenerative disorders.

View Vigil Neuroscience Profile

More Earnings Resources from MarketBeat